Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.
Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, Sjöström M, Shrestha R, Kneppers J, Severson T, Zhang M, Lundberg A, Moreno Rodriguez T, Weinstein AS, Foye A, Mehra N, Aggarwal RR, Bergman AM, Small EJ, Lack NA, Zwart W, Quigley DA, van der Heijden MS, Feng FY. Zhu X, et al. Among authors: van der heijden ms. J Clin Invest. 2024 Aug 13;134(19):e178604. doi: 10.1172/JCI178604. J Clin Invest. 2024. PMID: 39352383 Free PMC article.
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients.
Severson TM, Zhu Y, Prekovic S, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden M, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A, Wessels L, Corey E, Zwart W, Bergman AM. Severson TM, et al. medRxiv [Preprint]. 2023 Feb 24:2023.02.24.23286403. doi: 10.1101/2023.02.24.23286403. medRxiv. 2023. PMID: 36865297 Free PMC article. Preprint.
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, Koeppen H, Assaf ZJ, Nabet BY, Waddell A, Yuen K, Maund S, Sokol E, Giltnane JM, Schedlbauer A, Fuentes E, Cowan JD, Kadel EE 3rd, Degaonkar V, Andreev-Drakhlin A, Williams P, Carter C, Gupta S, Steinberg E, Loriot Y, Bellmunt J, Grivas P, Rosenberg J, van der Heijden MS, Galsky MD, Powles T, Mariathasan S, Banchereau R. Hamidi H, et al. Among authors: van der heijden ms. Cancer Cell. 2024 Nov 16:S1535-6108(24)00404-5. doi: 10.1016/j.ccell.2024.10.016. Online ahead of print. Cancer Cell. 2024. PMID: 39577421
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.
Stockem CF, Einerhand SMH, Rodríguez IM, Salhi Y, Pérez E, Bakaloudi DR, Talukder R, Caramelo B, Morales-Barrera R, De Meulenaere A, Rametta A, Bottelli A, Lefort F, Giannatempo P, Vulsteke C, Carles J, Duran I, Grivas P, de Liaño AG, Robbrecht DGJ, Valderrama BP, van der Noort V, van der Heijden MS. Stockem CF, et al. Among authors: van der heijden ms. BJC Rep. 2024 Oct 23;2(1):84. doi: 10.1038/s44276-024-00104-3. BJC Rep. 2024. PMID: 39516359 Free PMC article.
FGFR Inhibition in Urothelial Carcinoma.
Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. Li R, et al. Among authors: van der heijden ms. Eur Urol. 2024 Sep 30:S0302-2838(24)02605-8. doi: 10.1016/j.eururo.2024.09.012. Online ahead of print. Eur Urol. 2024. PMID: 39353825 Review.
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Powles T, et al. Among authors: van der heijden ms. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282910 Clinical Trial.
Integrated noninvasive diagnostics for prediction of survival in immunotherapy.
Yeghaian M, Bodalal Z, Tareco Bucho TM, Kurilova I, Blank CU, Smit EF, van der Heijden MS, Nguyen-Kim TDL, van den Broek D, Beets-Tan RGH, Trebeschi S. Yeghaian M, et al. Among authors: van der heijden ms. Immunooncol Technol. 2024 Jul 9;24:100723. doi: 10.1016/j.iotech.2024.100723. eCollection 2024 Dec. Immunooncol Technol. 2024. PMID: 39185322 Free PMC article.
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.
Necchi A, Van der Heijden MS, Trukhin D, Peer A, Gurney H, Alekseev BY, Parnis FX, Leibowitz R, De Santis M, Grivas P, Clark J, Munteanu M, Kataria R, Jia C, Balar AV, de Wit R. Necchi A, et al. Among authors: van der heijden ms. BMC Cancer. 2024 Jul 25;23(Suppl 1):1252. doi: 10.1186/s12885-023-10727-3. BMC Cancer. 2024. PMID: 39054491 Free PMC article. Clinical Trial.
138 results